Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to $28.1 million.

  • Perspective Therapeutics' Operating Expenses rose 4771.35% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.8 million, marking a year-over-year increase of 10257.21%. This contributed to the annual value of $92.3 million for FY2024, which is 11791.15% up from last year.
  • As of Q3 2025, Perspective Therapeutics' Operating Expenses stood at $28.1 million, which was up 4771.35% from $24.3 million recorded in Q2 2025.
  • Over the past 5 years, Perspective Therapeutics' Operating Expenses peaked at $45.2 million during Q4 2024, and registered a low of $2.1 million during Q1 2021.
  • Over the past 5 years, Perspective Therapeutics' median Operating Expenses value was $10.2 million (recorded in 2023), while the average stood at $13.0 million.
  • As far as peak fluctuations go, Perspective Therapeutics' Operating Expenses crashed by 559.01% in 2021, and later surged by 27640.89% in 2024.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Operating Expenses stood at $2.9 million in 2021, then soared by 96.88% to $5.6 million in 2022, then surged by 113.72% to $12.0 million in 2023, then surged by 276.41% to $45.2 million in 2024, then tumbled by 37.92% to $28.1 million in 2025.
  • Its Operating Expenses was $28.1 million in Q3 2025, compared to $24.3 million in Q2 2025 and $22.2 million in Q1 2025.